Thyrocare Approves Rs 141 Crore Nueclear Sale To Trovera

Board approved sale of 100% in Nueclear Healthcare to Trovera for Rs 141.4 Cr (Rs 59.5 Cr via 42,500 CCPS plus Rs 81.9 Cr cash) and buy of Gurugram/Hyderabad labs for Rs 20.6 Cr. Exits capex-heavy radiology to focus capital on core asset-light pathology; follows Jul 23 in-principle nod. Retains operating labs via property buy; needs shareholder special resolution. Frees management, adds cash plus 4.5% in 3-month-old Trovera with no financials; SPA unsigned, close by Nov 30; CCPS converts 1:1 on IPO filing or after 20 years.